{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T12:45:21Z","timestamp":1773751521717,"version":"3.50.1"},"reference-count":30,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"JSPS KAKENHI","doi-asserted-by":"publisher","award":["JP22K16352"],"award-info":[{"award-number":["JP22K16352"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Lymphoproliferative disorders (LPDs) are adverse effects of methotrexate (MTX) prescribed for rheumatoid arthritis (RA). Sj\u00f6gren\u2019s disease (SjD), for which the presence of anti-Ro\/SS-A antibodies (Abs) is a diagnostic criterion, might accompany RA and be a risk factor for LPDs. We conducted a retrospective study to analyze the effects of SjD or anti-Ro\/SS-A Ab positivity on the clinical course of patients with RA complicated by LPDs. Methods: We retrospectively analyzed 25 patients in our department who had RA complicated by LPDs, specifically collecting clinical information regarding the complications of SjD and positivity for anti-Ro\/SS-A Abs. Results: In total, 25 patients with RA were included in this study, 3 of which were diagnosed with SjD by attending physicians based on sicca symptoms and positiveness of anti-Ro\/SS-A antibodies. No significant differences in clinical characteristics except for SjD diagnosis given by attending physicians were found between the patients positive for anti-Ro\/SS-A Abs and the patients negative for anti-Ro\/SS-A Ab. The most common histologic LPD subtype was diffuse large B cell lymphoma, while mucosa-associated lymphoid tissue lymphoma, the histologic subtype often diagnosed as SjD-LPD, was found in only one patient, who was positive for anti-Ro\/SS-A Abs without an SjD diagnosis. There were no significant differences in the intervals between the RA and LPD diagnoses and those of SjD and anti-Ro\/SS-A Ab positivity. Conclusions: While the rate of anti-Ro\/SS-A Ab positivity in the study population seemed to be higher than that in the general RA population, any potential effects of SjD on RA-LPD development were not ascertained in this study.<\/jats:p>","DOI":"10.3390\/jcm15062271","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T09:35:57Z","timestamp":1773740157000},"page":"2271","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of Influences of Sj\u00f6gren\u2019s Disease and Anti-Ro\/SS-A Antibodies on Clinical Course of Patients with Rheumatoid Arthritis Complicated by Lymphoproliferative Disorders: A Pilot Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2366-3566","authenticated-orcid":false,"given":"Yoshiro","family":"Horai","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Sasebo City General Hospital, 9-3 Hirase-Cho, Sasebo 857-8511, Japan"},{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Kurushima","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Sasebo City General Hospital, 9-3 Hirase-Cho, Sasebo 857-8511, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5837-6348","authenticated-orcid":false,"given":"Hideki","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo 173-8610, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMra2103726","article-title":"Rheumatoid Arthritis\u2014Common Origins, Divergent Mechanisms","volume":"388","author":"Gravallese","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Asanuma, Y., Abe, Y., Yamaji, K., and Tamura, N. (2025). Retrospective Study of 68 Patients with Rheumatoid Arthritis-Associated Lymphoproliferative Diseases Treated with Methotrexate. Intern. Med., ahead of print.","DOI":"10.2169\/internalmedicine.5120-24"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_4","first-page":"S179","article-title":"Methotrexate as the \u201canchor drug\u201d for the treatment of early rheumatoid arthritis","volume":"21","author":"Pincus","year":"2003","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/mr\/road098","article-title":"Japan College of Rheumatology guidance for the use of methotrexate in patients with rheumatoid arthritis: Secondary publication","volume":"34","author":"Kameda","year":"2024","journal-title":"Mod. Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1111\/cas.15894","article-title":"Lymphoproliferative disorder risk after methotrexate treatment for rheumatoid arthritis","volume":"114","author":"Tanaka","year":"2023","journal-title":"Cancer Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1200\/JCO.1996.14.6.1943","article-title":"Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases","volume":"14","author":"Salloum","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Horai, Y., Kurushima, S., Shimizu, T., Nakamura, H., and Kawakami, A. (2025). A Review of the Impact of Sj\u00f6gren\u2019s Syndrome and\/or the Presence of Anti-Ro\/SS-A Antibodies on Therapeutic Strategies for Rheumatoid Arthritis. J. Clin. Med., 14.","DOI":"10.3390\/jcm14020568"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Horai, Y., Kurushima, S., Shimizu, T., Nakamura, H., and Kawakami, A. (2025). A Review of the Current Clinical Aspects of Sj\u00f6gren\u2019s Disease: Geographical Difference, Classification\/Diagnostic Criteria, Recent Advancements in Diagnostic Methods, and Molecular Targeted Therapy. J. Clin. Med., 14.","DOI":"10.3390\/jcm14155577"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2013-203305","article-title":"Primary Sjogren\u2019s syndrome and malignancy risk: A systematic review and meta-analysis","volume":"73","author":"Liang","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sj\u00f6gren\u2019s syndrome: A revised version of the European criteria proposed by the American-European Consensus Group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"ACR-EULAR classification criteria for primary Sj\u00f6gren\u2019s syndrome: A consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.3899\/jrheum.101295","article-title":"Anti-Ro\/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis","volume":"38","author":"Matsudaira","year":"2011","journal-title":"J. Rheumatol."},{"key":"ref_14","first-page":"234","article-title":"Points to note when using MTX: Lymphoproliferative disorders","volume":"35","author":"Inokuma","year":"2023","journal-title":"Rinsho Riumachi. Clin. Rheumatol. Rel. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheumatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3121\/cmr.2017.1341","article-title":"Pulmonary MALT lymphoma in patients with Sj\u00f6gren\u2019s syndrome","volume":"15","author":"Yachoui","year":"2017","journal-title":"Clin. Med. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e70363","DOI":"10.1111\/1756-185x.70363","article-title":"Incidence and Risk of Malignancy in Japanese Patients With Rheumatoid Arthritis in the National Database of Rheumatic Diseases in Japan (NinJa Database)","volume":"28","author":"Matsui","year":"2025","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/14397595.2020.1866837","article-title":"Overall survival and post-spontaneous regression relapse-free survival of patients with lymphoproliferative disorders associated with rheumatoid arthritis: A multi-center retrospective cohort study","volume":"32","author":"Saito","year":"2022","journal-title":"Mod. Rheumatol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Takanashi, S., and Kaneko, Y. (2024). Unmet Needs and Current Challenges of Rheumatoid Arthritis: Difficult-to-Treat Rheumatoid Arthritis and Late-Onset Rheumatoid Arthritis. J. Clin. Med., 13.","DOI":"10.3390\/jcm13247594"},{"key":"ref_20","first-page":"322","article-title":"Lymphoproliferative disorders in rheumatoid arthritis: Clinicopathological analysis of 76 cases in relation to methotrexate medication","volume":"34","author":"Hoshida","year":"2007","journal-title":"J. Rheumatol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Iizuka, N., Hoshida, Y., Miyamoto, A.T., Shigyo, H., Nishigaichi, A., Okamura, G., and Ohshima, S. (2025). Immunosuppressants\/ImmunomodulatorsandMalignancy. J. Clin. Med., 14.","DOI":"10.3390\/jcm14145160"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1136\/annrheumdis-2015-208426","article-title":"Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study)","volume":"75","author":"Kaneko","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/14397595.2019.1641934","article-title":"Discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab: An interventional study","volume":"30","author":"Asai","year":"2020","journal-title":"Mod. Rheumatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/art.42809","article-title":"Effect of recent antirheumatic drug on features of rheumatoid arthritis-associated lymphoproliferative disorders","volume":"76","author":"Hoshida","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/acr.21812","article-title":"Serious Infections in a Population-Based Cohort of 86,039 Seniors with Rheumatoid Arthritis","volume":"65","author":"Widdifield","year":"2013","journal-title":"Arthritis Care Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/mr\/roac017","article-title":"Drug Treatment Algorithm and Recommendations from the 2020 update of the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis-Secondary Publication","volume":"33","author":"Kawahito","year":"2023","journal-title":"Mod. Rheumatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/bjh.17456","article-title":"Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs","volume":"194","author":"Harada","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1111\/1756-185X.14920","article-title":"Effectiveness and safety of rituximab in special types of rheumatoid arthritis","volume":"26","author":"Takanashi","year":"2023","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/mr\/roaf006","article-title":"2024 Update of the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis: Secondary publication","volume":"35","author":"Harigai","year":"2025","journal-title":"Mod. Rheumatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/6\/2271\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T11:31:24Z","timestamp":1773747084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/6\/2271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["jcm15062271"],"URL":"https:\/\/doi.org\/10.3390\/jcm15062271","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]}}}